Accueil・Liste d'Actions・Axsome Therapeutics Inc

Axsome Therapeutics Inc

Ouvert

SecteurSoins de santé

204.51 -1.15

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

205

Max

207.95

Chiffres clés
By Trading Economics
Revenu	13M -51M
Ventes	27M 218M
BPA	-0.99
Marge bénéficiaire	-23.498
Employés	1,346
EBITDA	11M -50M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+40.06% upside

Dividendes
By Acuity
Prochains Résultats	2 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	468M 11B
Ouverture précédente	205.66
Clôture précédente	204.51

Sentiment de l'Actualité

By Acuity

34%

66%

95 / 340 Classement par Healthcare

Axsome Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 août 2026, 19:41 UTC

Axsome Therapeutics Inc. shares are lower today, retracing from earlier gains and remaining below the 20-day moving average amid rising Treasury yields.

20 août 2026, 20:01 UTC

Axsome Therapeutics Inc's shares are declining amid broader market pressures from Walmart's disappointing earnings, raising concerns about consumer spending.

17 août 2026, 19:16 UTC

Axsome Therapeutics Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

14 août 2026, 19:36 UTC

Axsome Therapeutics Inc shares are higher today, rebounding from an earlier pullback, despite a broader market influenced by a decline in retail sales.

13 août 2026, 19:56 UTC

Axsome Therapeutics Inc shares are declining, retracing from earlier session highs amid broader market trends and rising U.S. unemployment claims.

12 août 2026, 22:36 UTC

Axsome Therapeutics shares higher in after-market trading, with no specific news identified. Broader market stability follows recent inflation data easing rate hike concerns.

11 août 2026, 19:45 UTC

Social Media

News

Axsome Therapeutics shares are lower following a second-quarter loss of 99 cents per share, missing the consensus estimate of 83 cents.

10 août 2026, 23:06 UTC

Axsome Therapeutics Inc shares are lower during after-market hours amid mixed market sentiment. The stock is trading below its 20-day moving average.

7 août 2026, 19:52 UTC

Axsome Therapeutics Inc shares are higher during Friday's session, recovering from a brief dip after reaching a session high. No specific news was identified.

6 août 2026, 23:01 UTC

Axsome Therapeutics Inc. is trading higher in after-market hours, showing stability despite no specific news. The stock remains below its 20-day moving average.

5 août 2026, 19:36 UTC

Axsome Therapeutics Inc shares are lower, pulling back from earlier session highs. The stock remains significantly below its 20-day moving average.

4 août 2026, 23:36 UTC

Axsome Therapeutics Inc shares are trading higher in after-market hours. Broader market dynamics may be influencing sentiment amid record highs in stock markets.

3 août 2026, 22:16 UTC

Axsome Therapeutics Inc shares are higher in after-market hours, despite no specific news. The stock showed unusual activity amid broader market dynamics.

31 juil. 2026, 22:01 UTC

Axsome Therapeutics Inc shares are higher in after-market trading, reflecting strong interest despite no specific news. The stock remains below its 20-day moving average.

30 juil. 2026, 19:28 UTC

Axsome Therapeutics Inc is rising during Thursday's session, reversing four consecutive lower closes. The stock remains below its 20-day moving average.

29 juil. 2026, 22:01 UTC

Axsome Therapeutics Inc shares are lower in after-market trading, closing below their 20-day moving average amid broader market caution and geopolitical tensions.

28 juil. 2026, 19:51 UTC

Axsome Therapeutics Inc shares are lower today, breaking a trend of higher daily closes amid broader market declines, particularly in Asian markets.

27 juil. 2026, 20:14 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, continuing a three-session trend. No specific news was identified to explain the movement.

24 juil. 2026, 23:51 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, reflecting a notable decline since Friday's close, with no specific news identified.

22 juil. 2026, 19:11 UTC

Axsome Therapeutics Inc shares are trading higher during Wednesday's session, reaching a high earlier before pulling back slightly amid increased market volume.

21 juil. 2026, 19:51 UTC

Social Media

News

BMO Capital initiated coverage on Axsome Therapeutics with an Outperform rating and a $310 price target, contributing to a rise in shares today.

20 juil. 2026, 21:21 UTC

News

BMO Capital initiated coverage on Axsome Therapeutics with an Outperform rating and a $310 price target. Shares are trading higher in after-market hours.

Comparaison

Variation de prix

Axsome Therapeutics Inc prévision

Objectif de Prix

By TipRanks

40.06% hausse

Prévisions sur 12 Mois

Moyen 291 USD 40.06%

Haut 380 USD

Bas 251 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

13 ratings

Achat

Maintien

Vente

Basé sur 13 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

95 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.